Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

Share on facebook
Share on twitter
Share on linkedin

April, 2019: BioAegis Therapeutics Receives US Patent Protection for the Therapeutic Uses of Plasma Gelsolin in Renal Failure

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 30, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing recombinant human plasma gelsolin (pGSN) announced today that the United States Patent Office has issued a patent for the Use of Plasma Gelsolin to Diagnose and Treat Renal Failure.

Read the full press release here: Renal Patent 2019